Moderna is pausing a patent dispute with the federal government over its coronavirus vaccine, saying it wants to “avoid any distraction” in the fight against the omicron variant
The decision could have implications for the Biden administration’s global vaccination strategy, as officials look for leverage to share mRNA vaccine discoveries with developing countries in an effort to ramp up worldwide supply.
“The Company would like to avoid any distraction to the important public-private efforts ongoing to address emerging SARS-CoV-2 variants, including Omicron,” Moderna said in a statement on Friday night shared with The Washington Post. Moderna also said it filed a continuation that will allow it to pursue discussions about the patent at a later date.of its plan to drop the patent application at a Dec. 10 meeting, a Moderna spokesperson said.requests for comment.
— which had never turned a profit before the pandemic — owes its success to the U.S. government. The company was staked with about $2.5 billion in federal funds to develop its vaccine last year, and has since received billions more to boost its manufacturing capacity.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
To Avoid Holiday Baking Burnout, Be Your Own Prep CookWhen I already have a recipe to work from (and anticipate being short on time), I’ll home in on specific components I can knock out a day or two in advance. — Pastry chef Joy Cho
Weiterlesen »
Jim Cramer rips SPACs, urges investors to avoid the blank-check companies right nowThe 'Mad Money' host said everybody besides institutional money managers get 'the short end of the stick' in SPAC deals.
Weiterlesen »
Omicron May Require Fourth Vaccine Dose, Pfizer SaysThe new Omicron variant could make it more likely that people will need a fourth coronavirus vaccine earlier than expected, Pfizer officials said on Wednesday.
Weiterlesen »
Low-dose Pfizer-BioNTech vaccine fails in trial on 2 to 5 year oldsA low dose of the Pfizer-BioNTech coronavirus vaccine failed to produce an adequate response in children aged two through five years of age.
Weiterlesen »